HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

gadodiamide (Omniscan)

Subscribe to New Research on gadodiamide

for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions

Also Known As:

Omniscan; Amersham brand of gadodiamide; Gd-DTPA bis-(methylamide); Gd-DTPA-BMA; Nycomed brand of gadodiamide; Omniscan Unique Softpack; Sanofi Winthrop brand of gadodiamide; Gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate

Networked: 232 relevant articles (21 outcomes, 29 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Thomsen, Henrik S: 8 articles (12/2012 - 09/2006)
2.	Nakashima, Tsutomu: 7 articles (03/2013 - 02/2011)
3.	Sone, Michihiko: 7 articles (03/2013 - 02/2011)
4.	Naganawa, Shinji: 7 articles (03/2013 - 02/2011)
5.	Marckmann, Peter: 7 articles (05/2008 - 09/2006)
6.	Yamazaki, Masahiro: 6 articles (03/2013 - 10/2011)
7.	Idée, Jean-Marc: 5 articles (08/2015 - 02/2011)
8.	Fretellier, Nathalie: 4 articles (08/2015 - 02/2011)
9.	Kawai, Hisashi: 4 articles (03/2013 - 01/2012)
10.	Bokura, Kiminori: 4 articles (03/2013 - 01/2012)

Related Diseases

1.	Neoplasms (Cancer) 08/01/1993 - "A phase III trial was conducted in 40 patients with known or suspected skull base tumors to evaluate the safety and efficacy of high-dose gadodiamide injection for use as a paramagnetic contrast medium in conventional and dynamic magnetic resonance (MR) imaging. " 02/01/1996 - "Gd-DTPA-BMA is effective for magnetic resonance imaging of musculoskeletal lesions and improves assessment of the tumor structure. " 12/01/2008 - "In contrast, a control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min postinjection. " 09/01/2001 - "In order to document the safety, tolerability and efficacy of gadodiamide outside CNS, an open, non-drug comparative study was performed in patients with tumors of the head and neck region. " 09/01/2009 - "Since intravenously injected gadodiamide is diluted from 500 microM to 1 mM by patient blood flow at enhanced MRI examinations, the results of the present study suggest that gadodiamide has not effect on these types of cancer cells."
2.	Body Weight (Weight, Body) 11/01/1996 - "Gadodiamide injection (0.1 mmol/kg body weight) was safe and effective in infants, children and adolescents." 11/01/1996 - "The safety and efficacy of intravenous gadodiamide injection, 0.1 mmol/kg body weight, have been evaluated in an open label, non-comparative as to drug, phase III clinical trial in 50 children from 6 months to 13 years of age, referred for MRI requiring the injection of a contrast medium. " 02/01/1996 - "Dynamic studies were performed using a FLASH 2D-gradient-echo sequence (TR 40 ms/TE 10 ms, 90 degrees flip angle) every 20 s after intravenous bolus injection of Gd-DTPA-BMA (0.3 mmol/kg body weight). " 01/01/1996 - "Data on vital signs, clinical laboratory parameters, and subjectively experienced adverse events were reviewed for 734 patients included in 19 European Phase II and III trials with gadodiamide injection (0.1 mmol/kg body weight or 0.3 mmol/kg body weight) used in magnetic resonance imaging. " 11/01/2009 - "High-dose gadodiamide was administered, 2.5 mmol per kilogram of body weight for 20 days, or 500 times the U.S. "
3.	Renal Artery Obstruction (Renal Artery Stenosis) 12/01/2007 - "To determine the most efficacious dose of gadodiamide for three-dimensional (3D) contrast-enhanced (CE) magnetic resonance angiography (MRA) of the renal arteries on a patient level based on the sensitivity in detecting the main hemodynamically relevant (> or =50% or occlusion) renal artery stenosis (RAS) using intra-arterial digital subtraction angiography (IA DSA) as the gold standard. " 02/01/2010 - "To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard. " 02/01/2010 - "Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: results of a phase III multicenter trial." 05/01/2001 - "Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency." 03/01/1999 - "To determine whether gadodiamide is a safe and useful angiographic contrast agent for help in diagnosis and percutaneous treatment of renal artery stenosis in patients with renal insufficiency. "
4.	Nephrogenic Fibrosing Dermopathy 06/01/2009 - "The purpose of our study was to evaluate the prevalence of nephrogenic systemic fibrosis (NSF) and nephrotoxicity among patients with differing degrees of renal dysfunction who are exposed to high doses of gadodiamide. " 09/01/2006 - "This study therefore reviewed all of the authors' confirmed cases of nephrogenic systemic fibrosis (n = 13) with respect to clinical characteristics, gadodiamide exposure, and subsequent clinical course. " 04/01/2008 - "Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis." 03/01/2008 - "22 cases of gadodiamide-related nephrogenic systemic fibrosis followed at the nephrology department of Copenhagen University Hospital Herlev. " 03/01/2008 - "Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis."
5.	Myocardial Infarction 05/01/1993 - "Improved and persistent contrast between infarcted and normal myocardium can be produced on MR images by injecting gadodiamide at a dose of 0.2 mmol/kg, which provides prolonged delineation of myocardial infarctions. " 03/01/2006 - "Forty-three patients with myocardial infarction were examined on a 1.5-T MR system 10 min after administration of contrast material (gadodiamide, 0.2 mmol/kg) with a single-shot 2D multislice technique (single-shot inversion recovery trueFISP) that allows one to image the entire short axis during one breath-hold (18 heartbeats) and with a segmented 2D single-slice technique (inversion recovery turboFLASH) that requires one breath-hold per slice (12 heartbeats). " 07/01/1998 - "Rats (n = 28) were subjected to reperfused myocardial infarction and received no contrast medium, 0.2, 0.5, or 1.0 mmol/kg Gd DTPA-BMA. " 10/01/1997 - "On Gd-DTPA-BMA-enhanced images, reperfused myocardial infarctions were homogeneously enhanced. " 11/01/1995 - "To investigate whether Gd-DTPA-BMA-enhanced MR imaging permits differentiation between reperfused and nonreperfused myocardial infarction, myocardial infarction was induced in 12 domestic pigs. "

Related Drugs and Biologics

1.	gadodiamide (Omniscan)
2.	Gadolinium DTPA (Magnevist)
3.	gadobenic acid (gadobenate dimeglumine)
4.	sprodiamide
5.	Erythropoietin
6.	Iron
7.	imatinib (Gleevec)
8.	ferryl iron (Fe(4+))
9.	Collagen
10.	Isosorbide

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Enema (Enemas)
3.	Laminectomy
4.	Peritoneal Dialysis
5.	Intravenous Injections